Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tanvir Singh

Child & Adolescent Psychiatry Toledo, OH Medical Doctor

NPI 1851322168 CMS profile 814134

3125 Transverse Dr, Toledo, OH 43614

Open in the dashboard

General payments

$2,056

126 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tanvir Singh of Toledo, OH is reported in the CMS Open Payments database as having received $2,056 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $22 1
2023 General $339 15
2022 General $241 14
2021 General $815 48
2020 General $154 10
2019 General $485 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tanvir Singh
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Tanvir Singh were reported at $22. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Tanvir Singh Child & Adolescent Psychiatry median Middle half National median
2019 $485 $129 $42–$419 $163
2020 $154 $81 $28–$226 $114
2021 $815 $115 $31–$326 $132
2022 $241 $124 $40–$382 $149
2023 $339 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $22 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $439 26 payments
  2. Sunovion Pharmaceuticals Inc. $329 24 payments
  3. Alkermes, Inc. $245 12 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $210 18 payments
  5. AbbVie, Inc. $196 10 payments
  6. ITI, Inc. $157 7 payments
  7. Lundbeck LLC $89 5 payments
  8. Indivior Inc. $59 4 payments
  9. Janssen Pharmaceuticals, Inc $45 3 payments
  10. Avanir Pharmaceuticals, Inc. $36 2 payments
  11. Other $251 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,996 124 payments
  2. Education $60 2 payments
Products named General payments · program years 2019–2025
  1. LATUDA $329 24 payments
  2. ABILIFY MAINTENA $249 14 payments
  3. REXULTI $234 15 payments
  4. LYBALVI $204 9 payments
  5. VRAYLAR $196 10 payments
  6. ARISTADA Cns $184 8 payments
  7. ARISTADA Cns $184 8 payments
  8. TRINTELLIX $174 12 payments
  9. CAPLYTA $157 7 payments
  10. ARISTADA Cns $107 4 payments
  11. Other $987 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

646

Median for Psychiatry: 574

Drug cost

$55,705

Median for Psychiatry: $27,624

Branded share of claims

6.3%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 16 $36,674
Aripiprazole Generic 32 $8,863
Oxcarbazepine Generic 14 $2,751
Bupropion Xl Bupropion Hcl Brand 14 $1,381
Buspirone Hcl Generic 22 $826
Alprazolam Generic 80 $668
Hydroxyzine Pamoate Generic 16 $609
Duloxetine Hcl Generic 36 $486
Methylphenidate Hcl Generic 16 $411
Ziprasidone Hcl Generic 14 $406

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$3,140

Medicare's payments for the services billed

Medicare patients

14

Average age 60

Services billed

49

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record